Literature DB >> 32654868

Non-alcoholic fatty liver disease: A review with clinical and pathological correlation.

Yen-Ying Chen1, Matthew M Yeh2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in North America and Europe, with increasing prevalence in other regions of the world. Its spectrum encompass steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. It is considered as the manifestation of metabolic syndrome in liver, and its development and progression is influenced by complex interaction of environmental and genetic factors. In this review we discuss the histopathological features, differential diagnoses, and the commonly used grading and staging systems of NAFLD. NAFLD associated with other diseases, histological changes after therapeutic intervention and recurrence or occurrence of NAFLD after liver transplantation are also addressed.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Year:  2020        PMID: 32654868     DOI: 10.1016/j.jfma.2020.07.006

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

Review 1.  Inflammation: A New Look at an Old Problem.

Authors:  Evgenii Gusev; Yulia Zhuravleva
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Authors:  Marcin Kosmalski; Sylwia Ziółkowska; Piotr Czarny; Janusz Szemraj; Tadeusz Pietras
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

3.  Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set.

Authors:  Zhengzheng Gao; Lina Dai; Haifeng Zhang
Journal:  Comput Math Methods Med       Date:  2022-04-16       Impact factor: 2.809

4.  Emerging Trends and Hot Spots in Hepatic Glycolipid Metabolism Research From 2002 to 2021: A Bibliometric Analysis.

Authors:  Yanyu Zhou; Xiaoqi Lin; Suqing Yin; Ling Zhu; Yuting Yang; Yixuan Li; Baoshan Wang; Yingfu Jiao; Weifeng Yu; Po Gao; Liqun Yang
Journal:  Front Nutr       Date:  2022-07-12

5.  Fuzi-Lizhong Decoction Alleviates Nonalcoholic Fatty Liver Disease by Blocking TLR4/MyD88/TRAF6 Signaling.

Authors:  Jiayao Yang; Ying Zhang; Hongfeng Yi; Yan Liao; Lei Shu; Shu Zhang; Chenyu Li; Liu An; Nianlong Du; Zhaohong Shi; Wei Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-26       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.